• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Ferraldeschi, Roberta
    Arnedos, M
    Hadfield, K D
    A'Hern, R
    Drury, S
    Wardley, Andrew M
    Howell, Anthony
    Evans, D G
    Roberts, S A
    Smith, I
    Newman, W G
    Dowsett, M
    Show allShow less
    Affiliation
    Department of Medical Oncology, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.
    Issue Date
    2012-03-15
    
    Metadata
    Show full item record
    Abstract
    Single nucleotide polymorphisms (SNPs) in the gene encoding aromatase (CYP19A1) have been associated with differential benefit from letrozole treatment in metastatic breast cancer (mBC) patients, but validation is lacking. The aim was to investigate whether polymorphic variation of CYP19A1 and enzymes involved in estrogen and aromatase inhibitors (AIs) metabolism are associated with efficacy of AIs. 308 Women with estrogen-receptor-positive metastatic mBC treated with a third-generation AI were identified retrospectively. DNA was extracted from archival formalin-fixed paraffin embedded tumors and genotyped for 71 variants in 16 candidate genes, including CYP19A1. Time to treatment failure (TTF) was significantly improved in patients carrying the minor (T) allele of rs4775936 when compared to patients with the reference allele [HR = 0.79 per T allele (0.66-0.95); P = 0.012]. Patients with >7 TTTA repeats on either allele of CYP19A1 intron 4 had a lower risk of failure than those with a smaller repeat size [HR = 0.84 per >7 TTTA repeats (0.7-0.99); P = 0.04]. However, importantly in multivariate analysis, adjusting for the number of disease sites; disease-free interval from diagnosis to first recurrence, grade at diagnosis and first recurrence type neither variant maintained independent predictive significance. None of the 56 SNPs analyzed as an exploratory set showed significant association with TTF. Variants in CYP19A1 or other selected genes associated with AI metabolism were not independently associated with improved AI efficacy and emphasize the importance in pharmacogenetic studies of considering genetic biomarkers in the context of relevant prognostic factors.
    Citation
    Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients. 2012,133(3):1191-8 Breast Cancer Res Treat
    Journal
    Breast Cancer Research and Treatment
    URI
    http://hdl.handle.net/10541/230799
    DOI
    10.1007/s10549-012-2010-z
    PubMed ID
    22418701
    Type
    Article
    Language
    en
    ISSN
    1573-7217
    ae974a485f413a2113503eed53cd6c53
    10.1007/s10549-012-2010-z
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • A polymorphism at the 3'-UTR region of the aromatase gene is associated with the efficacy of the aromatase inhibitor, anastrozole, in metastatic breast carcinoma.
    • Authors: Liu L, Bai YX, Zhou JH, Sun XW, Sui H, Zhang WJ, Yuan HH, Xie R, Wei XL, Zhang TT, Huang P, Li YJ, Wang JX, Zhao S, Zhang QY
    • Issue date: 2013 Sep 13
    • Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.
    • Authors: Umamaheswaran G, Kadambari D, Muthuvel SK, Kalaivani S, Devi J, Damodaran SE, Pradhan SC, Dubashi B, Dkhar SA, Adithan C
    • Issue date: 2020 Jul
    • Research on aromatase gene (CYP19A1) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer.
    • Authors: Miron L, Negură L, Peptanariu D, Marinca M
    • Issue date: 2012 Oct-Dec
    • S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer.
    • Authors: Shao X, Cai J, Zheng Y, Wang J, Feng J, Huang Y, Shi L, Chen Z, Guo Y, Wang X
    • Issue date: 2015
    • Pharmacogenetics of aromatase inhibitors.
    • Authors: Hadfield KD, Newman WG
    • Issue date: 2012 Apr
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.